Repligen (RGEN) Tops Q4 EPS by 5c; offers guidance

Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.49, $0.05 better than the analyst estimate of $0.44. Revenue for the quarter came in at $197.91 million versus the consensus estimate of $192.89 million.

GUIDANCE:

Repligen sees FY2026 EPS of $1.93-$2.01, versus the consensus of $2.07. Repligen sees FY2026 revenue of $810-840 million, versus the consensus of $823.9 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• Alpha's Drilling Confirms Second Target of Scale at Anagulu Copper-Gold Porphyry Project